% alzhub.org library filter
% Source: https://alzhub.org/research?author=Andersen+SW&score_min=67
% 5 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{mintun2021-33720637,
  author  = {Mintun, M. A. and Lo, A. C. and Duggan Evans, C. and Wessels, A. M. and Ardayfio, P. A. and Andersen, S. W. and Shcherbinin, S. and Sparks, J. and others},
  title   = {{Donanemab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2021},
  doi     = {10.1056/nejmoa2100708},
  pmid    = {33720637},
  url     = {https://doi.org/10.1056/nejmoa2100708}
}

@article{wessels2020-31764959,
  author  = {Wessels, A. M. and Tariot, P. N. and Zimmer, J. A. and Selzler, K. J. and Bragg, S. M. and Andersen, S. W. and Landry, J. and Krull, J. H. and others},
  title   = {{Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials}},
  journal = {JAMA neurology},
  year    = {2020},
  doi     = {10.1001/jamaneurol.2019.3988},
  pmid    = {31764959},
  url     = {https://doi.org/10.1001/jamaneurol.2019.3988}
}

@article{wang2025-40172303,
  author  = {Wang, H. and Serap Monkul Nery, E. and Ardayfio, P. and Khanna, R. and Otero Svaldi, D. and Gueorguieva, I. and Shcherbinin, S. and Andersen, S. W. and Hauck, P. M. and Engle, S. E. and others},
  title   = {{Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70062},
  pmid    = {40172303},
  url     = {https://doi.org/10.1002/alz.70062}
}

@article{shcherbinin2022-36094645,
  author  = {Shcherbinin, S. and Evans, C. D. and Lu, M. and Andersen, S. W. and Pontecorvo, M. J. and Willis, B. A. and Gueorguieva, I. and Hauck, P. M. and others},
  title   = {{Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.2793},
  pmid    = {36094645},
  url     = {https://doi.org/10.1001/jamaneurol.2022.2793}
}

@article{fleisher2024-38386949,
  author  = {Fleisher, A. S. and Munsie, L. M. and Perahia, D. G. S. and Andersen, S. W. and Higgins, I. A. and Hauck, P. M. and Lo, A. C. and Sims, JR. and others},
  title   = {{Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease}},
  journal = {Neurology},
  year    = {2024},
  doi     = {10.1212/wnl.0000000000208061},
  pmid    = {38386949},
  url     = {https://doi.org/10.1212/wnl.0000000000208061}
}